Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 878-884

  Hinsche, Oliver ^a   Girgert, Rainer ^a   Emons, Günter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ER ; Invasion; Metastasis; Migration; Triple negative breast cancer

Indexed keywords

ANTIMETASTATIC AGENT; CHEMOKINE RECEPTOR CXCR4; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA SELECTIVE AGONIST; HORMONE RECEPTOR AFFECTING AGENT; LIQUIRITIGENIN; PRINABEREL; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; ESTROGEN; ESTROGEN RECEPTOR ALPHA, HUMAN; FLAVANONE DERIVATIVE; OXAZOLE DERIVATIVE;

ARTICLE; BASEMENT MEMBRANE; BONE METASTASIS; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; WESTERN BLOTTING; AGONISTS; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; OXAZOLES; RECEPTORS, CXCR4; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918529695     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2778     Document Type: Article

References (26)

1. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB and Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37: 1217-1226, 2006.
2. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
3. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER )-negative, progesterone receptor (PR)-negative, and HER 2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007.
4. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13: 1033-1067, 2006.
5. Tomin R and Donegan WL: Screening for recurrent breast cancer - its effectiveness and prognostic value. J Clin Oncol 5: 62-67, 1987.
6. Schlappack OK, Baur M, Steger G, Dittrich C and Moser K: The clinical course of lung metastases from breast cancer. Klin Wochenschr 66: 790-795, 1988.
7. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC and Clavien PA: Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127: 383-389, 2000.
8. von Alten J, Fister S, Schulz H, et al: GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 100: 13-21, 2006.
9. Olbrich T, Ziegler E, Türk G, Schubert A, Emons G and Gründker C: Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose-window effect. Gynecol Oncol 119: 571-578, 2010.
10. Lindberg K, Ström A, Lock JG, Gustafsson JA, Haldosén LA and Helguero LA: Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 222: 156-167, 2010.
11. Marotti JD, Collins LC, Hu R and Tamimi RM: Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 23: 197-204, 2010.
12. Chen JQ and Russo J: ER alpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 1796: 162-175, 2009.
13. Sakamoto G and Honma N: Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer. Breast Cancer 16: 281-282, 2009.
14. Schmidt E, Haase M, Ziegler E, Emons G and Gründker C: Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells. Int J Gynecol Cancer 24: 210-217, 2014.
15. Girgert R, Emons G and Gründker C: Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat 134: 199-205, 2012.
16. Mersereau JE, Levy N, Staub RE, et al: Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 283: 49-57, 2008.
17. Shanle EK, Hawse JR and Xu W: Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Biochem Pharmacol 82: 1940-1949, 2011.
18. Liu Y, Xie S, Wang Y, Luo K and Cai Y: Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells. Molecules 17: 7206-7216, 2012.
19. Chaudhary SC, Singh T, Talwelkar SS, et al: Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SK H-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila) 7: 186-198, 2014.
20. Samanta S, Sharma VM, Khan A and Mercurio AM: Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer. Oncogene 31: 4689-4697, 2012.
21. Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
22. Chu QD, Panu L, Holm NT, Li BD, Johnson LW and Zhang S: High chemokine receptor CXCR 4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 159: 689-695, 2010.
23. Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS and Richmond A: CXCR 4 drives the metastatic phenotype in breast cancer through induction of CXCR 2 and activation of MEK and PI3K pathways. Mol Biol Cell 25: 566-582, 2014.
24. Sun Y, Mao X, Fan C, et al: CXCL 12-C XCR 4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol 35: 7765-7773, 2014.
25. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L and Shim H: Silencing of CXCR 4 blocks breast cancer metastasis. Cancer Res 65: 967-971, 2005.
26. Li HY, Ren GS and Tan JX: The effects of shRNA-C XCR 4 on breast cancer cells migration and invasion. Sichuan Da Xue Xue Bao Yi Xue Ban 40: 393-397, 2009 (In Chinese).